Your session is about to expire
← Back to Search
Trastuzumab Emtansine for Cancer
Study Summary
This trial is testing if ado-trastuzumab emtansine can shrink or stop the growth of cancer that has a genetic change called HER2 amplification.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 3 trial • 444 Patients • NCT02131064Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I agree to use effective birth control or abstain from sex during and for 7 months after the study.My heart's pumping ability is confirmed to be normal by a recent heart scan.My hemoglobin level is at least 9.0 g/dL.I have not been treated with specific FDA-approved or investigational HER2 drugs.I do not have breast or stomach cancer.I am not allergic to ado-trastuzumab emtansine or similar drugs.I do not have severe nerve damage.My tumor has a high level of HER2 based on a specific genetic test.I am on blood thinners (not warfarin) or take 81 mg aspirin daily.My recent ECG showed no significant heart issues.
- Group 1: Treatment (trastuzumab emtansine)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are allowed to enroll in this clinical trial?
"This study is not currently enrolling patients. However, it is still possible to find other trials; as of right now, there are 4810 clinical trials for refractory lymphomas and 43 for Trastuzumab Emtansine that are actively looking for participants."
Are there harmful side effects associated with Trastuzumab Emtansine?
"Trastuzumab Emtansine is at a Phase 2 in terms of testing, so while there is some data supporting its safety, none supports its efficacy. Our team rates it as a 2 on our scale."
What are the precedent studies for Trastuzumab Emtansine?
"As of now, 43 clinical trials are underway to research Trastuzumab Emtansine. Of these, 9 are in Phase 3. Most of the studies for Trastuzumab Emtansine are located in Brewer, Maine; however, there are 6088 locations running clinical trials for Trastuzumab Emtansine across the world."
Has this research been conducted before?
"Trastuzumab Emtansine has undergone 43 clinical trials in 1456 cities and 57 countries since the first study in 2008. The initial trial, sponsored by Hoffmann-La Roche, completed Phase 2 drug approval stage with 720 patients. In the 12 years since then, 36 more studies have been conducted."
Are participants being accepted for this experiment at this time?
"This particular study is not enrolling patients at the current moment. However, it is important to note that there are 4810 other clinical trials for refractory lymphomas and 43 trials for Trastuzumab Emtansine still admitting participants."
Share this study with friends
Copy Link
Messenger